Stock listing

NASDAQ:IFRX InflaRx N.V. Stock

Home listing (NASDAQ) of InflaRx N.V.

Follow InflaRx N.V. into a list and get an email when it puts out news.

Share price · NASDAQ:IFRX

$1.04 USD -0.07 (-6.3%)

Close on Nov 20, 2026

Past year -9.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.03 – $1.12 USDNov 20, 2026
Volume
472,105 sharesNov 20, 2026
Market cap
$153.3M USDAt the close on Nov 20, 2026 · price × 147.4M shares outstanding
52-week range
$0.798 – $2.95 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.47M USDMedian day 572,036 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
InflaRx N.V. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IFRX · Home$1.04 USD-0.07 (-6.3%)472,105$1.06$1.116$1.03$1.11Close on Nov 20, 2026
Frankfurt:IF0€0.949 EUR+0.001 (+0.1%)1,500€0.937€0.949€0.937€0.948Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IFRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.04-0.07-6.3%$1.06$1.116$1.03472,105
$1.11-0.04-3.5%$1.18$1.20$1.063,047,840
$1.15-0.03-2.5%$1.205$1.225$1.0851,987,465
$1.18+0.01+0.9%$1.16$1.225$1.151,037,318
$1.17-0.07-5.6%$1.23$1.239$1.15220,953
$1.24+0.06+5.1%$1.21$1.25$1.15883,021
$1.18-0.03-2.5%$1.30$1.30$1.17577,512
$1.21-0.10-7.6%$1.30$1.40$1.21283,775
$1.31+0.005+0.4%$1.30$1.34$1.211450,551
$1.305-0.05-3.7%$1.22$1.32$1.171,083,088
$1.355-0.125-8.4%$1.46$1.51$1.351,616,055
$1.48-0.14-8.6%$1.64$1.719$1.331,898,352
$1.62-0.145-8.2%$1.67$1.715$1.4855,678,346
$1.765+0.105+6.3%$1.68$1.79$1.63799,788
$1.66-0.055-3.2%$1.71$1.72$1.621691,451
$1.715-0.015-0.9%$1.74$1.79$1.71306,538
$1.73+0.07+4.2%$1.67$1.74$1.65493,936
$1.66+0.085+5.4%$1.59$1.66$1.57513,063
$1.575+0.015+1.0%$1.56$1.615$1.54397,590
$1.56+0.03+2.0%$1.51$1.585$1.48889,583
$1.53-0.02-1.3%$1.55$1.60$1.51404,205
$1.55+0.01+0.6%$1.55$1.61$1.54701,424
$1.54+0.09+6.2%$1.45$1.61$1.44724,082
$1.45+0.13+9.8%$1.33$1.48$1.2852,806,396
$1.32-0.12-8.3%$1.47$1.475$1.291,535,098
$1.44-0.04-2.7%$1.47$1.53$1.43552,043
$1.48-0.07-4.5%$1.53$1.536$1.46585,673
$1.55-0.04-2.5%$1.59$1.605$1.54367,525
$1.59-0.01-0.6%$1.60$1.64$1.545467,926
$1.60+0.07+4.6%$1.55$1.695$1.546740,708
$1.53-0.03-1.9%$1.55$1.60$1.471,141,896
$1.56-0.02-1.3%$1.60$1.60$1.55460,353
$1.58-0.10-6.0%$1.69$1.78$1.565720,672
$1.68-0.04-2.3%$1.70$1.72$1.65701,007
$1.72+0.01+0.6%$1.74$1.80$1.72422,162
$1.71-0.09-5.0%$1.83$1.856$1.71369,955
$1.80-0.05-2.7%$1.87$1.89$1.80302,499
$1.85+0.03+1.6%$1.83$1.89$1.80268,404
$1.82-0.07-3.7%$1.88$1.954$1.80426,389
$1.89-0.04-2.1%$1.94$2.04$1.87399,901
$1.93-0.03-1.5%$1.97$2.02$1.89510,186
$1.96-0.12-5.8%$2.08$2.09$1.96564,758
$2.08-0.04-1.9%$2.12$2.19$2.041571,271
$2.12+0.03+1.4%$2.11$2.19$2.065345,149
$2.09+0.03+1.5%$2.07$2.11$2.025292,676
$2.06+0.02+1.0%$2.05$2.10$1.98657,951
$2.04+0.02+1.0%$2.02$2.069$1.99821,206
$2.02-0.10-4.7%$2.12$2.165$1.99579,599
$2.12+0.03+1.4%$2.15$2.20$2.10545,790
$2.09+0.04+2.0%$2.07$2.11$2.04334,148
$2.05-0.04-1.9%$2.05$2.07$1.98613,475
$2.09-0.08-3.7%$2.15$2.15$2.05759,750
$2.17-0.05-2.3%$2.19$2.26$2.11408,904
$2.22-0.01-0.4%$2.21$2.377$2.16393,942
$2.23-0.06-2.6%$2.30$2.371$2.18666,374
$2.29+0.13+6.0%$2.16$2.34$2.133572,036
$2.16+0.03+1.4%$2.12$2.27$2.09475,080
$2.13-0.10-4.5%$2.21$2.23$2.09447,811
$2.23-0.04-1.8%$2.28$2.37$2.21610,420
$2.27-0.15-6.2%$2.40$2.435$2.2451,405,954
$2.42-0.04-1.6%$2.45$2.50$2.331,714,705
$2.46+0.41+20.0%$2.06$2.46$2.013,894,358
$2.05-0.05-2.4%$2.10$2.11$2.03337,021
$2.10+0.08+4.0%$2.03$2.12$2.025419,898
$2.02-0.10-4.7%$2.12$2.15$2.005587,737
Ticker
NASDAQ:IFRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All InflaRx N.V. news

InflaRx N.V. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
27 in the last 12 months · 118 in all · newest Nov 6, 2026 · oldest 2020
Decks
37 decks · latest Nov 3, 2026

Where InflaRx N.V. is listed

ListingExchangeCountryCurrency
NASDAQ:IFRX · Home listing · This pageNASDAQUnited StatesUSD
Tradegate:IF0TradegateGermanyEUR
gettex:IF0gettexGermanyEUR
LS Exchange:A2H7A5LS ExchangeGermanyEUR
Frankfurt:IF0FrankfurtGermanyEUR
Lang & Schwarz:A2H7A5Lang & SchwarzGermanyEUR
Stuttgart:IF0StuttgartGermanyEUR
BOATS:IFRXBOATSUnited StatesUSD
BMV:IFRXNBMVMexicoMXN
Munich:IF0MunichGermanyEUR
BIVA:IFRXNBIVAMexicoMXN
Dusseldorf:IF0DusseldorfGermanyEUR
Hamburg:IF0HamburgGermanyEUR

Valuation

EV/sales 4,215× against a median of 74.5×: 8th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026

Enterprise value
$135.7M USD
P/E
Loss
EV/sales
4,215×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
19.5×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.61

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
InflaRx N.V. · NASDAQ:IFRXUS$153.3MUS$135.7Mn/a4,215×n/a19.5×n/a0.0×1.61
ImmuneOncia Therapeutics Inc. · KRX:424870US$160.0MUS$90.35Mn/an/an/a2.1×n/a0.0×n/a
Baijin Life Science Holdings Limited · HKEX:1466US$160.0MUS$158.1Mn/a13.9×n/a6.8×−42.4%0.1×n/a
Jiangsu Recbio Technology Co., Ltd. Class H · HKEX:2179US$157.3MUS$230.0Mn/a124×n/a2.1×n/a1.4×n/a
BioVersys AG · SIX:BIOVUS$154.1MUS$97.45Mn/a102×n/a2.9×n/a0.5×n/a
Polaris Group · TWSE:6550US$153.0MUS$154.8Mn/a75.1×n/a1.1×n/a0.5×n/a
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541US$152.0MUS$64.59Mn/a2.9×n/a1.6×−141.7%0.6×n/a
Saniona AB · OMXSTO:SANIONUS$151.6MUS$104.0M8.4×2.5×5.2×2.8×43.2%0.0×n/a
Palisade Bio, Inc. · NASDAQ:PALIUS$150.6MUS$36.96Mn/a73.9×n/a1.3×n/a0.0×1.41
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
Median of the othersUS$152.5MUS$100.7M8.4×74.5×5.2×2.1×−42.4%0.1×1.41

Forecasts

7 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
8.27 USD · Analysts' mean
EPS, year to Dec 2026
-0.20 · 3 analysts

Team and board

Officers

OfficerRole
Niels C. RiedemannChief Executive Officer and Founder
Thomas TaapkenChief Financial Officer
Christian SchmidVP, Head of Legal Affairs & General Counsel
Jan MedinaVice President, Head of Investor Relations
Derval O’CarrollSenior Vice President, Global Head of Regulatory Affairs & Compliance
Gabriela AlperovichSenior Vice President & Global Head of Clinical Development
Kofi BoatenVP, Head of Supply Quality & Clinical Trial Supplies
Maria HabelVP, Head of preclinical R&D and QC
Petra EßerVP, Head of Finance and Controlling
Daniel VetterSenior Director, Head of IT
Igor OrshanskiySenior Director, Head of Business Development
Kirsten CremeringSenior Director, Head of Quality Assurance
Peter HurtSenior Director, Head of Drug Safety and Pharmacovigilance
Renfeng GuoChief Scientific Officer and Founder
Tony GibneyBoard Member, Head of Audit Committee

Board

DirectorRole
Nicolas FulpiusChairman of the Board
Andreas Kronbichler
David JayneBoard Member
Hege HellstromBoard Member
Jonathan BarrattBoard Member
Jürgen FloegeBoard Member
Mark KublerBoard Member
med. Bernhard HellmichBoard Member
Ming-hui ZHAO
Peter A. MerkelBoard Member
Richard BrudnickBoard Member
Tony GibneyBoard Member, Head of Audit Committee

Events

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 3, 2026 · Before open−8.2%
Quarter to Jun 30, 2026Aug 6, 2026 · Before open−2.8%
Quarter to Mar 31, 2026May 13, 2026−2.1%
Quarter to Dec 31, 2025Mar 19, 2026 · Before open+3.4%
Quarter to Sep 30, 2025Nov 10, 2025 · Before open+28.5%
Q2 2025Aug 7, 2025 · Before open−3.0%
Quarter to Mar 31, 2025May 7, 2025 · Before open−7.5%
Quarter to Dec 31, 2024Mar 20, 20250.0%
Quarter to Sep 30, 2024Nov 8, 2024 · Before open+3.3%
Q2 2024Aug 8, 2024 · Before open−5.0%
All 20 quarters
QuarterResultsShare move
Quarter to Mar 31, 2024May 8, 2024 · Before open−3.2%
Quarter to Dec 31, 2023Mar 21, 2024 · Before open−8.9%
Quarter to Sep 30, 2023Nov 1, 2023 · Before open−4.1%
Q2 2023Aug 10, 2023 · Before open+9.6%
Quarter to Mar 31, 2023May 11, 2023 · Before open+7.5%
Quarter to Dec 31, 2022Mar 22, 2023 · Before open+10.7%
Quarter to Sep 30, 2022Nov 9, 2022 · Before open−1.8%
Q2 2022Aug 5, 2022 · Before open−5.2%
Quarter to Mar 31, 2022May 12, 2022 · Before open+6.6%
Quarter to Dec 31, 2021Mar 24, 2022 · Before open+5.6%

Open Events

Decks

DeckKindSlidesDate
Investor Day (November 2026)Investor day77 slidesNov 3, 2026
Investor Day (November 2026)Investor day76 slidesNov 3, 2026
Investor Presentation (August 2026)Investor deck37 slidesAugust 2026
Investor Presentation (May 2026)Investor deck38 slidesMay 6, 2026
Investor Presentation (May 2026)Investor deck38 slidesMay 2026
Investor Presentation (April 2026)Investor deck67 slidesApr 9, 2026
Investor Presentation (February 2026)Investor deck67 slidesFeb 25, 2026
Technical Presentation (November 2025)Technical43 slidesNov 10, 2025
Investor Presentation (August 2025)Investor deck49 slidesAugust 2025
Investor Presentation (May 2025)Investor deck55 slidesMay 2025
All 37 decks
DeckKindSlidesDate
Investor Presentation (January 2025)Investor deck55 slidesJan 15, 2025
Investor Presentation (August 2024)Investor deck54 slidesAugust 2024
Technical Presentation (June 2024)Technical87 slidesJun 5, 2024
Investor Presentation (June 2024)Investor deck54 slidesJune 2024
Investor Presentation (March 2024)Investor deck42 slidesMar 21, 2024
Investor Presentation (March 2024)Investor deck49 slidesMarch 2024
Technical Presentation (January 2024)Technical27 slidesJan 4, 2024
Investor Presentation (January 2024)Investor deck33 slidesJanuary 2024
Investor Presentation (September 2023)Investor deck39 slidesSeptember 2023
Technical Presentation (September 2023)Technical23 slidesSeptember 2023
Investor Presentation (June 2023)Investor deck39 slidesJune 2023
Investor Presentation (September 2022)Investor deck33 slidesSeptember 2022
Investor Presentation (May 2022)Investor deck34 slidesMay 2022
Leerink Partners Global Healthcare Conference 2022Conference39 slidesFeb 17, 2022
Investor Presentation (January 2022)Investor deck31 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck39 slidesNovember 2021
Technical Presentation (October 2021)Technical20 slidesOct 27, 2021
Investor Presentation (March 2021)Investor deck36 slidesMar 9, 2021
Investor Presentation (January 2021)Investor deck31 slidesJanuary 2021
Investor Presentation (September 2020)Investor deck32 slidesSeptember 2020
LifeSci Capital Alpha Series Conference 2020Conference32 slidesApr 8, 2020
SVB Leerink Global Healthcare Conference 2020Conference17 slidesFeb 26, 2020
JP Morgan Healthcare Conference 2020Conference35 slidesJan 16, 2020
Technical Presentation (November 2019)Technical32 slidesNov 14, 2019
Technical Presentation (November 2019)Technical14 slidesNovember 2019
Investor Presentation (May 2019)Investor deck37 slidesMay 8, 2019
Technical PresentationTechnical14 slides

Open Decks

Financings

RaiseDate
Public offering of ordinary shares and pre-funded warrants
Closed: US$30M raised · US$2 a share · Warrants at US$0.001 · Guggenheim Securities, LLC +2
Dealers: Guggenheim Securities, LLC (lead), H.C. Wainwright & Co. (co-lead), Lucid Capital Markets, LLC (co-lead)
Use of proceeds: Clinical development of pipeline candidates including vilobelimab and INF904, and general corporate purposes
Feb 18, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Fireman B.V. Priced at US$15.00 a share on Nov 7, 2017.

Price
US$15.00 a share
Shares offered
6,667,000 common shares
Offering size
US$100 million
Underwriters' option
Up to 1,000,050 more shares
Underwriters
J.P. Morgan, Leerink Partners, BMO Capital Markets · In the order on the cover
Shares delivered
On or about Nov 10, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceJun 23, 2017
Filed publiclyOct 13, 2017
Amended 4 timesNewest Nov 7, 2017
Shares registered with an exchangeNov 7, 2017
Declared effective by the SECNov 7, 2017
Final prospectus, with the priceNov 8, 2017

Open IPO · From the cover of the final prospectus (424B4) filed Nov 8, 2017

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue29.3K165.8K63.1K
Cost of revenue7.27M3.32M532.3K
Gross profit-7.24M-3.15M-469.2K-37.8M-19.6M-7.12M
Research and development25.7M35.4M41.0M37.5M35.7M25.7M44.6M25.0M14.4M5.28M
Selling, general and administrative16.0K41.4K95.2K97.4K105.8K8.47M12.5M12.8M5.14M1.84M
Operating income-44.9M-32.2M-47.6M
Depreciation and amortization419.5K485.1K567.8K596.6K669.4K712.7K663.2K173.6K70.9K33.0K
EBITDA-44.3M-31.6M-47.0M
Interest expense2.69K88516.5K23.3K10.7K18.7K004.92M2.05M
Income before tax-45.6M-46.1M-42.7M-29.5M-45.6M-34.0M-53.3M-29.8M-24.2M-8.94M
Income tax12.3K5.22K000000
Net income-45.6M-46.1M-42.7M-29.5M-45.6M-34.0M-53.3M-29.8M-24.2M-8.94M
Earnings per share, basic-0.68-0.78-0.78-0.67-1.10-1.26
Earnings per share, diluted-0.68-0.78-0.78-0.67-1.10-1.26

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents16.0M18.4M12.8M16.3M26.2M26.0M33.1M55.4M123.3M29.1M
Inventory6.90M11.4M
Current assets53.6M71.7M109.5M97.4M95.7M86.3M119.0M158.2M124.0M29.4M
Property, plant and equipment289.3K256.3K289.6K328.9K274.4K408.3K576.4K624.7K173.0K
Total assets55.2M76.0M120.2M102.4M125.1M88.2M121.6M159.2M124.2M29.5M
Accounts payable5.40M11.4M12.0M4.99M8.57M8.26M12.4M6.66M4.47M1.53M
Current liabilities13.0M14.2M16.8M13.0M18.8M10.1M14.1M7.76M4.77M1.75M
Long-term debt0
Total debt0
Total liabilities13.7M14.6M17.6M14.1M19.9M10.4M14.4M7.82M4.78M
Shareholders' equity7.17M7.44M7.38M7.26M105.3M77.9M107.1M151.4M119.4M-25.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-35.3M-48.6M-37.8M-33.7M-39.9M-36.5M-43.2M-21.5M-12.2M-4.99M
Cash from investing3.23M52.4M-17.7M19.4M-26.0M21.4M20.3M-99.4M-167.0K-53.0K
Cash from financing33.3M386.4K53.0M1.94M61.6M9.17M-294.3K49.6M108.8M30.9M
Change in cash1.24M4.19M-2.52M-12.4M-4.31M-5.99M-23.2M-71.4M94.2M25.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 6, 2026Current reportSEC
6-K · Report of a foreign issuerNov 3, 2026Current reportSEC
6-K · Report of a foreign issuerNov 3, 2026Current reportSEC
6-K · Report of a foreign issuerOct 22, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
424B5 · ProspectusAug 14, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveAug 13, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
F-3 · Registration statementAug 6, 2026Offer documentSEC
S-8 · Registration statement for employee plansAug 6, 2026Offer documentSEC
6-K · Report of a foreign issuerAug 6, 2026Current reportSEC
6-K · Report of a foreign issuerJun 30, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerMay 7, 2026Current reportSEC
424B5 · ProspectusMay 7, 2026Offer documentSEC
424B5 · ProspectusMay 6, 2026Offer documentSEC
6-K · Report of a foreign issuerMay 6, 2026Current reportSEC
6-K · Report of a foreign issuerMay 6, 2026Current reportSEC
6-K · Report of a foreign issuerMay 4, 2026Current reportSEC
6-K · Report of a foreign issuerApr 28, 2026Current reportSEC
6-K · Report of a foreign issuerApr 23, 2026Current reportSEC
6-K · Report of a foreign issuerApr 9, 2026Current reportSEC
6-K · Report of a foreign issuerApr 2, 2026Current reportSEC
20-F · Annual reportMar 20, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 13, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 8, 2026Current reportSEC
6-K · Report of a foreign issuerDec 30, 2025Current reportSEC
6-K · Report of a foreign issuerNov 10, 2025Current reportSEC
6-K · Report of a foreign issuerNov 10, 2025Current reportSEC
6-K · Report of a foreign issuerSep 12, 2025Current reportSEC
6-K · Report of a foreign issuerAug 7, 2025Current reportSEC
6-K · Report of a foreign issuerJul 14, 2025Current reportSEC
6-K · Report of a foreign issuerJun 27, 2025Current reportSEC
UPLOAD · Letter from the SECJun 11, 2025Other filingsSEC
CORRESP · Letter to the SECJun 3, 2025Other filingsSEC
6-K · Report of a foreign issuerMay 28, 2025Current reportSEC
UPLOAD · Letter from the SECMay 22, 2025Other filingsSEC
6-K · Report of a foreign issuerMay 7, 2025Current reportSEC
6-K · Report of a foreign issuerApr 24, 2025Current reportSEC
6-K · Report of a foreign issuerApr 3, 2025Current reportSEC
20-F · Annual reportMar 20, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 20, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
424B5 · ProspectusFeb 18, 2025Offer documentSEC
424B5 · ProspectusFeb 13, 2025Offer documentSEC
6-K · Report of a foreign issuerJan 15, 2025Current reportSEC
6-K · Report of a foreign issuerDec 20, 2024Current reportSEC
6-K · Report of a foreign issuerNov 15, 2024Current reportSEC
6-K · Report of a foreign issuerNov 8, 2024Current reportSEC
6-K · Report of a foreign issuerAug 8, 2024Current reportSEC
424B5 · ProspectusJun 28, 2024Offer documentSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
6-K · Report of a foreign issuerJun 24, 2024Current reportSEC
6-K · Report of a foreign issuerJun 5, 2024Current reportSEC
6-K · Report of a foreign issuerMay 21, 2024Current reportSEC
6-K · Report of a foreign issuerMay 8, 2024Current reportSEC
6-K · Report of a foreign issuerApr 25, 2024Current reportSEC
6-K · Report of a foreign issuerApr 4, 2024Current reportSEC
6-K · Report of a foreign issuerMar 21, 2024Current reportSEC
20-F · Annual reportMar 21, 2024Annual reportSEC
6-K · Report of a foreign issuerMar 21, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 25, 2024Current reportSEC
6-K · Report of a foreign issuerJan 4, 2024Current reportSEC
6-K · Report of a foreign issuerNov 6, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
6-K · Report of a foreign issuerSep 11, 2023Current reportSEC
6-K · Report of a foreign issuerAug 30, 2023Current reportSEC
6-K · Report of a foreign issuerAug 10, 2023Current reportSEC
424B5 · ProspectusJul 12, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 12, 2023Other filingsSEC
CORRESP · Letter to the SECJul 7, 2023Other filingsSEC
UPLOAD · Letter from the SECJul 6, 2023Other filingsSEC
F-3 · Registration statementJun 30, 2023Offer documentSEC
6-K · Report of a foreign issuerJun 28, 2023Current reportSEC
6-K · Report of a foreign issuerJun 21, 2023Current reportSEC
6-K · Report of a foreign issuerMay 11, 2023Current reportSEC
6-K · Report of a foreign issuerApr 27, 2023Current reportSEC
SC 13G · Big-stake noticeApr 24, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeApr 17, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerApr 13, 2023Current reportSEC
424B5 · ProspectusApr 13, 2023Offer documentSEC
424B5 · ProspectusApr 11, 2023Offer documentSEC
6-K · Report of a foreign issuerApr 5, 2023Current reportSEC
6-K · Report of a foreign issuerApr 4, 2023Current reportSEC
20-F · Annual reportMar 22, 2023Annual reportSEC
6-K · Report of a foreign issuerMar 22, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerJan 5, 2023Current reportSEC
6-K · Report of a foreign issuerDec 21, 2022Current reportSEC
6-K · Report of a foreign issuerNov 9, 2022Current reportSEC
6-K · Report of a foreign issuerNov 9, 2022Current reportSEC
6-K · Report of a foreign issuerSep 29, 2022Current reportSEC
6-K · Report of a foreign issuerSep 8, 2022Current reportSEC
6-K · Report of a foreign issuerAug 5, 2022Current reportSEC
6-K · Report of a foreign issuerJul 26, 2022Current reportSEC
6-K · Report of a foreign issuerJul 6, 2022Current reportSEC
6-K · Report of a foreign issuerJun 29, 2022Current reportSEC
6-K · Report of a foreign issuerMay 12, 2022Current reportSEC
6-K · Report of a foreign issuerApr 28, 2022Current reportSEC
6-K · Report of a foreign issuerApr 7, 2022Current reportSEC
6-K · Report of a foreign issuerMar 31, 2022Current reportSEC
20-F · Annual reportMar 24, 2022Annual reportSEC
6-K · Report of a foreign issuerMar 24, 2022Current reportSEC
6-K · Report of a foreign issuerMar 17, 2022Current reportSEC
6-K · Report of a foreign issuerMar 8, 2022Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2022Current reportSEC
6-K · Report of a foreign issuerFeb 16, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 3, 2022Current reportSEC
6-K · Report of a foreign issuerJan 10, 2022Current reportSEC
6-K · Report of a foreign issuerJan 5, 2022Current reportSEC
6-K · Report of a foreign issuerNov 15, 2021Current reportSEC
6-K · Report of a foreign issuerNov 5, 2021Current reportSEC
6-K · Report of a foreign issuerOct 27, 2021Current reportSEC
6-K · Report of a foreign issuerOct 19, 2021Current reportSEC
6-K · Report of a foreign issuerOct 12, 2021Current reportSEC
6-K · Report of a foreign issuerSep 15, 2021Current reportSEC
6-K · Report of a foreign issuerSep 8, 2021Current reportSEC
6-K · Report of a foreign issuerAug 26, 2021Current reportSEC
6-K · Report of a foreign issuerAug 10, 2021Current reportSEC
6-K · Report of a foreign issuerAug 10, 2021Current reportSEC
6-K · Report of a foreign issuerAug 5, 2021Current reportSEC
6-K · Report of a foreign issuerJun 8, 2021Current reportSEC
6-K · Report of a foreign issuerMay 21, 2021Current reportSEC
6-K · Report of a foreign issuerMay 12, 2021Current reportSEC
6-K · Report of a foreign issuerMay 11, 2021Current reportSEC
6-K · Report of a foreign issuerMay 3, 2021Current reportSEC
6-K · Report of a foreign issuerApr 15, 2021Current reportSEC
20-F · Annual reportMar 25, 2021Annual reportSEC
6-K · Report of a foreign issuerMar 25, 2021Current reportSEC
SC 13G · Big-stake noticeMar 8, 2021Big-stake noticeSEC
SC 13G · Big-stake noticeMar 8, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerMar 1, 2021Current reportSEC
424B5 · ProspectusFeb 26, 2021Offer documentSEC
424B5 · ProspectusFeb 24, 2021Offer documentSEC
6-K · Report of a foreign issuerFeb 24, 2021Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 16, 2021Big-stake noticeSEC
6-K · Report of a foreign issuerJan 11, 2021Current reportSEC
6-K · Report of a foreign issuerJan 5, 2021Current reportSEC
6-K · Report of a foreign issuerOct 29, 2020Current reportSEC
6-K · Report of a foreign issuerSep 17, 2020Current reportSEC
6-K · Report of a foreign issuerSep 14, 2020Current reportSEC
6-K · Report of a foreign issuerAug 6, 2020Current reportSEC
S-8 · Registration statement for employee plansJul 30, 2020Offer documentSEC
6-K · Report of a foreign issuerJul 30, 2020Current reportSEC
6-K · Report of a foreign issuerJul 21, 2020Current reportSEC
424B5 · ProspectusJul 20, 2020Offer documentSEC
6-K · Report of a foreign issuerJul 20, 2020Current reportSEC
EFFECT · Notice that a registration is effectiveJul 20, 2020Other filingsSEC
6-K · Report of a foreign issuerJul 16, 2020Current reportSEC
CORRESP · Letter to the SECJul 16, 2020Other filingsSEC
F-3/A · Registration statement, amendedJul 16, 2020Offer documentSEC
UPLOAD · Letter from the SECJul 15, 2020Other filingsSEC
F-3 · Registration statementJul 8, 2020Offer documentSEC
6-K · Report of a foreign issuerJun 30, 2020Current reportSEC
6-K · Report of a foreign issuerJun 17, 2020Current reportSEC
6-K · Report of a foreign issuerMay 21, 2020Current reportSEC
20-F · Annual reportApr 29, 2020Annual reportSEC
6-K · Report of a foreign issuerApr 29, 2020Current reportSEC
6-K · Report of a foreign issuerApr 9, 2020Current reportSEC
6-K · Report of a foreign issuerMar 31, 2020Current reportSEC
6-K · Report of a foreign issuerMar 2, 2020Current reportSEC
6-K · Report of a foreign issuerFeb 26, 2020Current reportSEC
SC 13D · Big-stake noticeFeb 14, 2020Big-stake noticeSEC
SC 13D · Big-stake noticeFeb 14, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2020Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2020Big-stake noticeSEC
6-K · Report of a foreign issuerJan 16, 2020Current reportSEC
6-K · Report of a foreign issuerNov 14, 2019Current reportSEC
6-K · Report of a foreign issuerNov 7, 2019Current reportSEC
6-K · Report of a foreign issuerAug 14, 2019Current reportSEC
6-K · Report of a foreign issuerJul 18, 2019Current reportSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2019Big-stake noticeSEC
6-K · Report of a foreign issuerJun 14, 2019Current reportSEC
SC 13G/A · Big-stake notice, amendedJun 14, 2019Big-stake noticeSEC
6-K · Report of a foreign issuerJun 13, 2019Current reportSEC
6-K · Report of a foreign issuerJun 5, 2019Current reportSEC
6-K · Report of a foreign issuerMay 23, 2019Current reportSEC
6-K · Report of a foreign issuerMay 23, 2019Current reportSEC
6-K · Report of a foreign issuerMay 14, 2019Current reportSEC
6-K · Report of a foreign issuerMay 8, 2019Current reportSEC

This page holds 200 of 291 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from InflaRx N.V.’s releases · as of Feb 18, 2025

Common shares
147,368,221
Fully diluted
147,368,221

Fully diluted

LineShares
Common shares147,368,221

Warrants and options

Lot
Warrants · US$0.001 · expiry not stated

Share count over time

CountShares
Nov 22, 2026147,368,221

Open Cap table

Shareholders

HolderSharesValueAs of
Fidelity Small Cap Growth Fund3.29MUS$5.59MJul 31, 2026
Fidelity Advisor Biotechnology Fund3.2MUS$5.43MJul 31, 2026
Fidelity Small Cap Growth K6 Fund1.68MUS$2.85MJul 31, 2026
Franklin Biotechnology Discovery Fund376KUS$639KJul 31, 2026
Fidelity Nasdaq Composite Index Fund43,672US$105KMay 31, 2026
Tiff Multi-Asset Fund23,128US$51,807Jun 30, 2026
Total Stock Market Index Trust1,363US$3,053Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anthony S Gibney
Other companies: Aura Biosciences, Inc. (See Remarks · Since at least May 13, 2025)
Director · Since at least Mar 18, 2026
Andreas KronbichlerDirector · Since at least Nov 3, 2026
Christian SchmidVP, Head of Legal Affairs & General Counsel · Since at least Nov 5, 2026
Daniel VetterSenior Director, Head of IT · Since at least Nov 5, 2026
David JayneBoard Member · Since at least Nov 3, 2026
Derval O’CarrollSenior Vice President, Global Head of Regulatory Affairs & Compliance · Since at least Nov 5, 2026
Gabriela AlperovichSenior Vice President & Global Head of Clinical Development · Since at least Oct 2, 2026
Hege HellstromBoard Member · Since at least Nov 5, 2026
Igor OrshanskiySenior Director, Head of Business Development · Since at least Nov 5, 2026
Jan MedinaVice President, Head of Investor Relations · Since at least Nov 3, 2026
All 27 people
PersonSeat
Jonathan BarrattBoard Member · Since at least Nov 3, 2026
Jürgen FloegeBoard Member · Since at least Nov 3, 2026
Kirsten CremeringSenior Director, Head of Quality Assurance · Since at least Nov 5, 2026
Kofi BoatenVP, Head of Supply Quality & Clinical Trial Supplies · Since at least Nov 5, 2026
Maria HabelVP, Head of preclinical R&D and QC · Since at least Nov 5, 2026
Mark KublerBoard Member · Since at least Mar 18, 2026
med. Bernhard HellmichBoard Member · Since at least Nov 3, 2026
Ming-hui ZHAODirector · Since at least Nov 3, 2026
Nicolas FulpiusChairman of the Board · Since at least Mar 18, 2026
Niels C. RiedemannChief Executive Officer and Founder · Since at least Mar 18, 2026
Peter A. MerkelBoard Member · Since at least Nov 3, 2026
Peter HurtSenior Director, Head of Drug Safety and Pharmacovigilance · Since at least Nov 5, 2026
Petra EßerVP, Head of Finance and Controlling · Since at least Nov 5, 2026
Renfeng GuoChief Scientific Officer and Founder · Since at least Mar 18, 2026
Richard BrudnickBoard Member · Since at least Nov 5, 2026
Thomas TaapkenChief Financial Officer · Since at least Aug 6, 2026
Tony GibneyBoard Member, Head of Audit Committee · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about InflaRx N.V.